76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
STAAR Surgical Co
Open
SectorHealthcare
19.17 5.68
Overview
Share price change
24h
Min
18.21
Max
19.46
Income | -20M -54M |
|---|---|
Sales | -6.4M 43M |
P/E Sector Avg | 55.443 56.602 |
EPS | -1.005 |
Profit margin | -127.289 |
Employees | 1,157 |
EBITDA | -43M -71M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | -1.32% downside |
Next Earnings | 6 Aug 2025 |
|---|
Market Cap | 211M 1B |
|---|---|
Previous open | 13.49 |
Previous close | 19.17 |
News Sentiment
By Acuity
7%
93%
1 / 382 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
STAAR Surgical Co Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
STAAR Surgical Co Forecast
Price Target
By TipRanks
-1.32% downside
12 Months Forecast
Average 17.2 USD -1.32%
High 20 USD
Low 13 USD
Based on 8 Wall Street analysts offering 12 month price targets forSTAAR Surgical Co - Dist in the last 3 months.
Sentiment
By Acuity
1 / 382 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About STAAR Surgical Co
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
